Resuming antiplatelet remedy following a subdural hematoma presents a posh scientific decision-making situation. The choice hinges on balancing the danger of recurrent hemorrhage in opposition to the potential for thromboembolic occasions, significantly in sufferers with underlying cardiovascular or cerebrovascular illness. Concerns embrace the scale and stability of the hematoma, the affected person’s total danger profile, and the indication for antiplatelet medicine.
The avoidance of thromboembolic problems is a major concern in sufferers requiring antiplatelet brokers. Untimely cessation can result in important morbidity and mortality. Nonetheless, restarting such drugs too early after a subdural hematoma will increase the danger of rebleeding and subsequent neurological deterioration. Traditionally, administration was typically conservative, involving extended antiplatelet discontinuation, however more moderen information recommend earlier resumption could also be thought of in fastidiously chosen sufferers.
